Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IL2 | P60568 | 6/20 | 0.51 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | STIM1 | Q13586 | 3/20 | 0.38 |
| ▸ | ORAI1 | Q96D31 | 3/20 | 0.38 |
| ▸ | ORAI2 | Q96SN7 | 1/20 | 0.38 |
| ▸ | CSNK1D | P48730 | 2/20 | 0.38 |
| ▸ | CSNK1E | P49674 | 2/20 | 0.38 |
| ▸ | ABL1 | P00519 | 1/20 | 0.37 |
| ▸ | CRACR2A | Q9BSW2 | 1/20 | 0.37 |
| ▸ | TRPC1 | P48995 | 1/20 | 0.36 |
| ▸ | TRPC3 | Q13507 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5998369 | 0.92 | IL2 (0.45) | IL2NPC1RAB9ASMN1; SMN2KDM4E | |
| SCHEMBL5999509 | 0.82 | IL2 (0.54) | IL2ALDH1A1STIM1ORAI1ORAI2 | |
| SCHEMBL5998902 | 0.78 | IL2 (0.42) | IL2NPC1RAB9ASMN1; SMN2KDM4E | |
| SCHEMBL15395982 | 0.77 | IL2 (0.55) | IL2NPC1RAB9ASMN1; SMN2KDM4E | |
| SCHEMBL15395972 | 0.74 | IL2 (0.67) | IL2NPC1RAB9ASMN1; SMN2KDM4E | |
| SCHEMBL12155970 | 0.74 | IL2 (0.52) | IL2NPC1RAB9ASMN1; SMN2TP53 | |
| SCHEMBL5550479 | 0.73 | IL2 (0.51) | IL2NPC1RAB9ASMN1; SMN2KDM4E | |
| SCHEMBL17092817 | 0.73 | IL2 (0.49) | IL2NPC1RAB9ASMN1; SMN2TDP1 | |
| SCHEMBL12155598 | 0.73 | STIM1 (0.65) | IL2NPC1RAB9ASMN1; SMN2TDP1 | |
| SCHEMBL12155899 | 0.73 | IL2 (0.59) | IL2NPC1RAB9ASMN1; SMN2TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9493427-B2 | Compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2016-11-15 | — | — | US | disclosed |
| EP-1848435-B1 | COMPOUNDS AGAINST INFLAMMATIONS AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP (US) | 2016-01-20 | — | — | EP | disclosed |
| US-20150266829-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | PRCL Research Inc. (CA) | 2015-09-24 | — | — | US | disclosed |
| US-9090570-B2 | Compounds for inflammation and immune-related uses | PRCL Research Inc. (CA) | 2015-07-28 | — | — | US | disclosed |
| US-20130309272-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2013-11-21 | — | — | US | disclosed |
| US-8518950-B2 | pyrazinyl, pyrimidinyl and pyridazinyl derivatives such asN-[5-(2-Chloro-5-trifluoromethyl-phenyl)-pyrazin-2-yl]-2,6-difluoro-benzamide, used as immunosuppressants for the treatmet or prevent inflammatory and immune disorders | SYNTA PHARMACEUTICALS CORP. (US) | 2013-08-27 | — | — | US | disclosed |
| US-20060173021-A1 | pyrazinyl, pyrimidinyl and pyridazinyl derivatives such asN-[5-(2-Chloro-5-trifluoromethyl-phenyl)-pyrazin-2-yl]-2,6-difluoro-benzamide, used as immunosuppressants for the treatmet or prevent inflammatory and immune disorders | SYNTA PHARMACEUTICALS CORP. (US) | 2006-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150266829-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | CCR1, CCR9, CXCR2 | IL2 21/4885NPC1 158/4885RAB9A 787/4885 |
| US-20130309272-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | CCR1, CCR9, CXCR2 | IL2 22/4885NPC1 164/4885RAB9A 787/4885 |
| US-20060173021-A1 | pyrazinyl, pyrimidinyl and pyridazinyl derivatives such asN-[5-(2-Chloro-5-trifluoromethyl-phenyl)-pyrazin-2-yl]-2,6-difluoro-benzamide, used as immunosuppressants for the treatmet or prevent inflammatory and immune disorders | TPMT, IL5, NAT1 | IL2 9/4885NPC1 643/4885RAB9A 500/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.